Background: Mixed-species otitis media caused by Streptococcus pneumoniae (Spn) and nontypeable Haemophilus influenzae (NTHi) is associated with complex manifestations that are less common in pneumococcal infections without NTHi. We analyzed the microbiological composition of middle ear fluid (MEF) cultures and nasopharyngeal samples obtained before PCV7/13 rollout to identify bacterial factors influencing single-and mixed-species disease progression.
INTRODUCTION
Otitis media (OM) has historically been the leading cause of healthcare visits, antimicrobial prescribing, and surgical procedures among young children in high-income countries (1) . Streptococcus pneumoniae (Spn) and nontypeable Haemophilus influenzae (NTHi) are the pathogens most commonly isolated from middle-ear fluid (MEF) in OM. Commensal carriage of these and other bacterial species in the upper-respiratory tract is the reservoir for middle-ear infection. Clinical severity ranges from acute or even asymptomatic presentations to complex OM (e.g., recurrent, nonresponsive, spontaneously-draining, or chronic OM and OM with effusion).
Formation of polymicrobial biofilms involving NTHi and Spn has recently been recognized as a risk factor for complex OM manifestations (2, 3) . In comparison to pneumococcal OM episodes where NTHi is not present, mixed-species episodes involving Spn and NTHi more often occur secondary to previous OM, are associated with recurrence and chronicity, and involve pneumococcal serotypes typically believed to be less virulent than those causing episodes without NTHi involvement, notably including pneumococcal serotypes not targeted by conjugate vaccines (PCV7/10/13) (2, 4) .
Because nearly all children carry Spn and NTHi in the first years of life, factors influencing progression from colonization to OM are ideal targets for treating or preventing disease. However, determinants of pathogenesis for Spn and NTHi are not well understood. Epidemiological studies in diverse settings have shown the species co-colonize the upper respiratory tract of children more frequently than would be expected by chance (5) (6) (7) (8) (9) . Cocolonization episodes feature elevated bacterial densities in both species, and entail pneumococcal serotypes that occur disproportionately in mixed-species OM: in comparison to serotypes colonizing the nasopharynx without NTHi, those found in co-colonization tend to have immune-evasive phenotypes favoring prolonged carriage duration (2, 4, (10) (11) (12) . NTHi enhances pneumococcal biofilm formation and persistence in the middle ear in chinchilla models of OM (13) , and the species aid one another in colonizing rats in nasal challenge experiments (14) . Nonetheless, the facilitative or competitive nature of species interactions remains unclear (15) (16) (17) , along with explanations for the distinct pneumococcal serotype distributions of singlespecies and mixed-species infections (2) .
We analyzed isolates from MEF and asymptomatic nasopharyngeal colonization to better understand bacterial determinants of OM progression. Using epidemiological surveillance data from southern Israel prior to PCV7/13 introduction, we compared pneumococcal serotype distributions of single-species and mixed-species carriage and OM, and measured pathogenspecific rates of OM progression from asymptomatic colonization. We found that pneumococcal serotype diversity is higher in mixed-species OM than single-species OM, despite reduced diversity among serotypes co-colonizing with NTHi in comparison to serotypes in single-species colonization. Immune-evasive pneumococcal phenotypes-which predict NTHi co-colonization (4)-have a weaker impact on progression of mixed-species infections in comparison to singlespecies infections. Our findings demonstrate that NTHi co-occurrence is associated with attenuated differences across pneumococcal serotypes in progression to OM.
RESULTS

Study enrollment
Data came from several studies undertaken prior to PCV7 introduction in southern Israel; we included samples obtained before July, 2008 in analyses ( Table 1) . Nasopharyngeal carriage of Spn and NTHi was monitored among PCV7/13-unvaccinated children ages 2 to 18 months old enrolled in a randomized trial of PCV7 dosing strategies between 2005 and 2008 (5, 18) . In total, children submitted 1588 samples, from which Spn was detected in 743 (46.8%) swabs; NTHi was detected in 524 (33.0%) swabs, and the two species were co-isolated in 376 (23.7%). A tenyear prospective study of the incidence of severe OM cases necessitating MEF culture (as indicated by complex manifestations; detailed in Materials and Methods) supplied 11,811 cases (2), with 4165 (35.3%) positive for Spn, 4813 (40.8%) positive for NTHi, and 1589 (13.5%) positive for the two species. Other previously-conducted laboratory and epidemiological studies supplied phenotype information about pneumococcal serotypes (12, (19) (20) (21) . Further descriptive details including age-specific OM incidence and carriage prevalence are included as supporting information (Figure S1 ).
Pneumococcal serotype distribution in single-species and mixed-species colonization and otitis media
If serotype factors play a role in progression of pneumococcal colonization to OM, the diversity of serotypes isolated from MEF would be expected to differ from the diversity of serotypes carried in the nasopharynx (4). To investigate this hypothesis, we calculated the Simpson's Diversity Index (D) for pneumococcal serotypes isolated from MEF and from carriage, with and without co-occurring NTHi, and tested for differences in serotype diversity (Figure 1) ; D measures the probability for any two randomly-chosen isolates to belong to different serotypes (see Materials and Methods).
Pneumococcal serotype diversity was higher in nasopharyngeal isolates than in MEF isolates both in the presence and in the absence of NTHi (p<10 -4 ). However, in mixed infections, the difference was no longer significant (p=0.11). Whereas serotype diversity was lower in the presence of NTHi during colonization, an opposite relationship was seen in MEF isolates, where diversity was significantly lower in single-species than in mixed-species infections (p=0.022).
We next sought to determine whether similar pneumococcal serotype diversity in mixed-species colonization and OM owed to the isolation of serotypes from nasopharyngeal and MEF samples at similar frequencies. We used Kullback-Leibler divergence to measure the relatedness of serotype distributions from single-species OM, single-species carriage, and mixed-species carriage to the serotype distribution of mixed-species OM (Figure 2) . We identified lower divergence between serotype distributions of mixed-species carriage and OM than between serotype distributions of single-species carriage and mixed-species OM (p<0.01). Divergence between the pneumococcal serotype distributions of mixed-species OM and single-species OM was lower, however, suggesting a role of pneumococcal serotype in both single-species and mixed-species OM progression.
Determinants of progression from colonization to OM
We next compared pathogen-specific rates of progression to OM episodes necessitating MEF in order to identify bacterial factors associated with virulence. We derived the odds ratio of disease as an expression for the relative rate of progression from asymptomatic colonization to OM (see Materials and Methods).
Progression rates for pneumococcal serotypes spanned over two orders of magnitude (Figure 3) . The highest progression rates were detected among PCV13 serotypes, including 1, 3, 5, and 7F; for the latter two serotypes, which were detected in 24 and 101 single-species OM cases respectively, no instances of single-species carriage were detected. Although we also detected no single-species carriage of 7B and 24F, these serotypes accounted for only 6 and 4 single-species OM episodes, respectively. Though not detected in mixed-species colonization, serotypes 8, 33F, and 15B/C were isolated from 4, 28, and 48 instances of mixed-species OM, respectively. Unencapsulated pneumococci had the lowest measured progression rates for single-species OM, while no instances of single-species OM involved serotypes 22F or 19B. We did not identify strong statistical evidence (defined by a 95% confidence interval entirely above one) that any serotype had a higher progression rate than NTHi.
Serotype differences in progression for mixed-species episodes were attenuated in comparison to differences in progression for single-species episodes. We identified lower progression rates in mixed-species episodes involving serotypes that tended otherwise to be virulent when colonizing in the absence of NTHi, including 6A, 6B, 14, 18C, 17F, 19A, 19F, and 31. Only nontypeable pneumococci and serotypes 20 and 31 showed increased progression rates in association with NTHi.
To understand this variation in progression to OM, we used regression models to calculate associations between phenotypes and progression rates for single-species and mixed-species episodes. Phenotypic attributes associated with fitness in colonization (greater ability to evade neutrophils, thicker encapsulation, and greater metabolic efficiency (12); stronger anionic charge (19) ; and higher case-fatality ratio in IPD (23)) predicted elevated rates of serotype-specific OM progression ( Table 2) , both in the presence and absence of NTHi. In addition, we identified that serotypes at high risk of causing IPD when carried (21) generally had lower rates of progression to OM. However, associations between pneumococcal phenotypes and progression rates were weaker for mixed-species episodes in comparison to single-species episodes. These analyses also revealed a 77.5% (46.3%, 114.5%) higher progression rate during the months with the highest degree of respiratory virus transmission (December to March), compounding elevated carriage prevalence during these months as a driver of seasonal OM incidence (5) .
DISCUSSION
We sought to better understand the progression of Spn and NTHi to complex OM manifestations using prospectively-gathered epidemiological surveillance data from Israel. In contrast to the finding that single-species pneumococcal OM episodes have lower serotype diversity than single-species pneumococcal carriage episodes, we did not identify differential diversity in carriage and OM when pneumococcal serotypes co-occur with NTHi. Identifying variation in the rates at which pneumococcal serotypes progress from colonization to OM in young children, we found that immune-evasive phenotypes predict higher rates of progression, and that this effect of pneumococcal phenotype is weaker in mixed-species episodes.
We also found that serotypes with high rates of progression to OM are distinct from those with high risk of causing IPD when carried (21, 24, 25) . This finding is consistent with previous studies (26, 27) , reaffirming a differential role of capsular factors in pathogenesis of mucosal diseases. The association of immune-evasive pneumococcal phenotype with higher rates of OM progression suggests pathogenesis may be influenced by the ability of robust serotypes to maintain higher bacterial density in the nasopharynx, or by the stronger inflammatory responses necessary to clear these serotypes from the nasopharynx and middle ear (28, 29) . Although our analysis does not characterize the contribution of viral infections to disease progression (30, 31) , their impact is suggested in our analysis by elevated progression rates during the winter months.
Several epidemiologic findings from our study corroborate the findings of laboratory studies addressing the impacts of microbial interaction on OM pathogenesis. Because mixed-species OM episodes frequently involve biofilm formation, the weaker associations we identify between pneumococcal capsular phenotype and mixed-species disease progression are consistent with previous evidence of down-regulated pneumococcal capsule expression in biofilms (32) . In addition, most serotypes did not show increased progression rates in the presence of NTHi in our analysis, similar to previous findings that mixed-species biofilms form "stable" infections with diminished risk of progressing to systemic disease in comparison to single-species infections (13) . The previously-reported tendency for children experiencing mixed-species OM to suffer severe symptoms (2) may thus partially reflect susceptibility to severe manifestations among children at risk for mixed-species OM progression (33) (34) (35) .
Our findings also aid interpretation of pneumococcal conjugate vaccine impact against OM. We found that pneumococcal serotypes included in PCV13 generally had higher rates of progression from colonization to OM in comparison to non-vaccine serotypes. This finding may explain why pneumococcal serotype replacement in carriage has not offset overall reductions in OM incidence following PCV7/13 rollout in Israel (22, 36) and other settings (37, 38) to the extent reported in IPD incidence (39) . Because tissue damage sustained during early-life OM episodes historically associated with PCV13 serotypes contributes to risk for secondary infections (34), PCV13-mediated protection against OM caused by these virulent agents may also contribute indirectly to reduced incidence of OM caused by other pathogens (22, 40) .
Our analysis has certain limitations. An ideal prospective study of OM progression would monitor nasopharyngeal carriage and OM incidence with MEF culture within a cohort of children to assess pathogen-specific OM incidence rates during colonization. Because the sample size needed to characterize serotype differences in progression would be prohibitively large in such a study, however, microbiologically-detailed prospective studies of carriage and disease provide a good alternative for characterizing pathogen-specific virulence (25) (26) (27) 40) . The validity of evaluating progression as OM incidence per carrier is suggested by meta-analytic findings of high concordance (>80%) in Spn and NTHi detection from nasopharyngeal and MEF cultures in severe OM cases (41) , such as those necessitating MEF culture in our study.
Nonetheless, molecular diagnostic tools may offer enhanced sensitivity in comparison to culture as performed here (42) (43) (44) .
It is important to note that our sample was enriched with complex OM cases due to the indications for obtaining MEF culture in the original prospective study. Thus, comparisons in our analysis reflect differences in progression to severe OM, and may not represent the broader spectrum of illness including acute OM episodes. While our analysis identified a higher progression rate for NTHi than certain pneumococcal serotypes, this may not owe entirely to differences in virulence between the species. In comparison to Spn, NTHi tends to be carried at older ages (Figure S1) , and has high colonization prevalence among otitis-prone children (35, 45) . High rates of progression for this pathogen may thus reflect its predominance in secondary infections following tissue damage associated with early-life OM (34) , in particular among otitisprone children (35) .
Our study provides data about species interactions between Spn and NTHi in children prior to the establishment of widespread immunity against virulent pneumococcal serotypes through routine PCV7/13 immunization. Our finding that the association between pneumococcal phenotype and OM progression rate is altered in the presence of NTHi helps to account for the distinct serotype distributions of single-species and mixed-species infections (2) .
METHODS
Setting
Previously-published studies provided data on incidence of severe OM necessitating MEF culture (22) and prevalence of bacterial carriage (5, 18) among Bedouin and Jewish children in the Negev region of southern Israel. The Bedouin population is transitioning from nomadic lifestyles to permanent settlements, and has larger family sizes, higher levels of overcrowding, and lower socioeconomic status in comparison to the nearby Jewish population (46). Bedouin children tend to experience higher rates of bacterial carriage and disease than Jewish children, despite receiving care from the same facilities (5) .
Datasets
OM incidence and carriage prevalence
Incidence of OM episodes necessitating MEF culture is monitored routinely at the Soroka University Medical Center (SUMC) through an ongoing prospective, population-based epidemiological surveillance program. Over 95% of children in the Negev region receive care at SUMC. Indications for MEF culture are based on clinical severity and include, but are not limited to, previous OM or tube insertion at any time, high-grade fever or toxic appearance, and spontaneous drainage, as detailed previously (22) ; these criteria have not changed during the study period.
Prevalence of nasopharyngeal Spn and NTHi carriage was monitored in a pre-implementation trial of PCV7 dosing schedules, wherein receipt of a first vaccine dose was randomized to between 2 and 18 months of age (18) ; data regarding pneumococcal and NTHi co-colonization have been published previously (4, 5) . We included data from all visits by unvaccinated children up to age 18 months.
Bacteriological procedures
Samples of MEF were obtained from tympanocentesis or spontaneous drainage and placed in MW173 Amies transport medium (Transwab; Medical Wire and Equipment, Potley, UK) before being plated, within 16 hours, on trypticase agar (5% sheep blood and 5 µg/mL gentamicin) and chocolate agar media, followed by 48 hours' incubation at 35ºC in 5% CO 2 . Laboratory procedures for identification of Spn and NTHi were consistent in the studies of carriage and MEF, and have been described previously (18) . Pneumococcal serotypes were determined by the Quellung reaction (antisera from Statens Serum Institut, Copenhagen, Denmark). Studies received ethics approval from SUMC, and secondary analyses were exempted by the institutional review board at Harvard TH Chan School of Public Health.
Pneumococcal serotype measurements
We used previously-obtained measurements of pneumococcal phenotypes in our analyses of factors associated with progression rate. These included the negative surface charge of the capsule (a determinant of susceptibility to phagocytosis) (19) ; the metabolic efficiency of capsule production, measured by the inverse of the number of carbons per repeat unit of the polysaccharide (12) ; the ability of serotypes to survive neutrophil-mediated killing in an in vitro surface assay (12) ; the width of the capsule (12); the likelihood for serotypes to cause death during invasive pneumococcal disease (IPD) (20) ; and the likelihood for serotypes to progress from carriage to IPD (21) .
Statistical analysis
Serotype distribution in carriage and otitis media
We measured serotype diversity (D) as
where p i values indicated the proportion of isolates belonging to serotype i. We used bootstrap resampling to measure confidence intervals around estimates and to test for differences in diversity in carriage and OM, applying a cluster bootstrap of children to account for repeated sampling in the carriage studies (4).
We used Kullback-Leibler divergence to measure similarity of the pneumococcal serotype distribution in mixed-species OM to the serotype distributions of the following clinical entities: pneumococcal OM without NTHi, pneumococcal carriage without NTHi, and mixed-species carriage of Spn and NTHi. We sampled from Dirichlet-multinomial posterior distributions of serotype frequencies, applying a flat (Jeffreys) prior to account for uncertainty in sparse observations (47). Measures closer to zero indicated greater similarity to the pneumococcal serotype distribution of mixed-species OM. Consistent with our analyses of Simpson diversity, we generated credible intervals and conducted hypothesis testing via the bootstrap for disease isolates, and via the cluster bootstrap for carriage isolates.
Variation in otitis media progression rate
Odds ratios calculated from counts (Y) of pathogen-specific carriage and disease episodes supplied the relative rate of progression from colonization to OM, measured as (cases/year)/carrier. The theoretical basis of this interpretation is as follows: defining the prevalence of colonization by agent(s) i as p i and the rate of OM incidence as , where PYAR(OM) and N(Car) refer to total person-years at risk for OM and children at risk for carriage, respectively, in the two datasets.
Based on the same premise, we used the odds ratio of OM to quantify the association between pneumococcal serotype factors and rate of progression from colonization to OM in the presence and absence of NTHi. Defining = > and ? > as the "baseline" rate of OM incidence and prevalence of colonization, respectively, and = @ A and ? @ A as the multiplicative impact of a serotype factor X on incidence and prevalence, respectively, ABC = ABC ABD ABD ABC = ( = > E= @ )( ? > ) ( = > )( ? > E? @ ) = = @ ? @ , which again represents the relative progression rate as the fold increase in incidence for X=1 (ref. X=0), normalized by any effect of X on carriage prevalence.
We used logistic regression to calculate odds ratios and adjusted odds ratios, controlling for the seasonal peak in virus transmission (months December to March) and Jewish or Bedouin ethnicity. Because differing numbers of children were retained in the unvaccinated group of the carriage study across ages, it was not possible to adjust for age in the odds ratio formulation above; however, the narrow age range considered (≤18 months) limits bias. We fitted models via generalized estimating equations with an exchangeable correlation structure to account for repeated sampling of children in the carriage studies. 
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TABLES
Invasiveness
Proportion of carriage events leading to IPD 36 serotypes 2 (21) 1 In vitro measurements of serotype properties were obtained from isogenic capsular-switch mutants 2 We list serotypes for which phenotypic data were collected in Table S1 . Table 1 . 2 Progression rates are compared via the odds ratio, as calculated by logistic regression with an exchangeable correlation structure to account for repeated carriage observations from individual children. Due to collinearity among serotype measurements, individual models are fitted for each association. Our derivation of the odds ratio as the relative progression rate is in the Methods. 3 Figure S1: Carriage prevalence and otitis media incidence among Jewish and Bedouin children. We calculated age-specific prevalence of Spn and NTHi carriage by fitting regression models with a log link function to data from scheduled visits at ages 2, 4, 6, 7, 12, and 18 months; we estimated the continuous trend over ages using a log transformation, which we determined was superior to first, second, or third-order polynomial terms via the Bayesian information criterion. We used an exchangeable correlation structure to account for repeated sampling of individual children. Incidence rate analyses were limited to data from 2004 to 2008 for compatibility with the timeframe of the carriage studies, and with previous studies of epidemiological circumstances preceding rollout of PCV7/13 in southern Israel (22, 40) .
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